Logo

Agenus Inc.

AGEN

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimul… read more

Healthcare

Biotechnology

23 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.95

Price

+2.47%

$0.10

Market Cap

$125.704m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$101.706m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$165.520m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$7.15

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$336.308m

$185.221m

Assets

$521.529m

Liabilities

$402.757m

Debt
Debt to Assets

217.5%

-5.2x

Debt to EBITDA
Free Cash Flow

-$127.362m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases